Summary sheet
Construction of a new central laboratory, a pilot plant for production of active pharmaceutical ingredients and the facilities in which the first commercial production will take place, as well as the related RDI activities.
The project will enable the promoter to undertake all parts of the pharmaceutical development process, from preclinical to clinical development, in-house.
RDI activities will not materially change current RDI practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. an EIA therefore is not required by EU Directive 97/11. The pilot plant construction and the expansion of the production facilities fall under annex II of the directive EC/97/11. Whether an EIA has been requested by the competent authorities or not, and environmental studies conducted will be verified during project appraisal.
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement.
Manufacturing
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).
News & Stories
General enquiries and comments
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
Media enquiries
Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.
Complaints mechanism
Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero tolerance against fraud and corruption
The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.
Related publications